Audited Result for the Financial Year March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chandra Bhagat Pharma Ltd (BSE-542934) announced its audited financial results for FY25 along with a clean (unmodified) auditor's opinion from M/s AY & Company. Profit before tax fell sharply to Rs 116.54 lakhs from Rs 226.19 lakhs in FY24, a drop of roughly 48%, indicating margin pressure. Operating cash flow turned negative at Rs (570.88) lakhs compared with a positive Rs 617.56 lakhs last year. Cash and bank balances plummeted to Rs 66.51 lakhs (from Rs 496.42 lakhs), while inventories dropped steeply from Rs 867.66 lakhs to Rs 69.19 lakhs. Total borrowings rose — long-term borrowings went up to Rs 228.35 lakhs (from Rs 141.33 lakhs) and short-term borrowings to Rs 1,857.65 lakhs (from Rs 1,501.35 lakhs).
While the unmodified audit opinion is reassuring, the steep fall in profits, negative operating cash flow, and sharply depleted cash reserves raise concerns about near-term financial health and could weigh on the stock sentiment.